Antipsychotic composition and method of treatment

• US 5,492,907 A
• Filed: 12/09/1992
• Issued: 02/20/1996
• Est. Priority Date: 12/09/1992
• Status: Expired due to Term

• Current Assignee: The United States of America As Represented By The Secretary of Agriculture
• Original Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Inventors: Pickar, David, Litman, Robert E., Potter, William Z.
• Primary Examiner(s): Shippen, Michael L.
• Application Number:
  US07/987,728
• Time in Patent Office: 1,168 Days
• Field of Search: 514/422, 514/211, 514/341, 514/280, 514/402, 514/223, 514/224, 514/215, 514/227, 514/225.8, 514/226.2, 514/253, 514/220, 514/235.2, 514/225.5, 514/397, 514/401
• US Class Current: 514/225.8
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/38 having sulfur as a ring hetero atom
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/475 having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine vincamine A61K31/4375
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/535 having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• CPC Class Codes: A61K 31/54 having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for treating a serious psychotic mental illness includes the step of administering to a patient in need of such treatment a combination of (i) an α₂ -adrenergic receptor antagonist and (ii) a D₂ dopamine receptor antagonist, A pharmaceutical composition useful in the novel method includes an effective amount of the combination of the foregoing two ingredients together with a pharmaceutically acceptable carrier.

Claims

1. A method for treating schizophrenia and schizoaffective illnesses comprising the step of administering to a patient in need of such treatment a therapeutically effective amount of a combination of (i) an α

₂ -adrenergic receptor antagonist, and (ii) a D₂ dopamine receptor antagonist in a pharmaceutically acceptable carrier,

wherein said α

₂ -adrenergic receptor antagonist (i) is one or more selected from the group consisting of idazoxan, yohimbine, ethoxy-idazoxan, fluperoxan and atipamezole, and

wherein said D₂ dopamine receptor antagonist (ii) is one or more antipsychotic neuroleptic drugs selected from the group consisting of thiopropazate, chlorpromazine, triflupromazine, mesoridazine, pipercetazine, thioridazine, acetophenazine, fluphenazine, perphenazine, trifluoperazine, chlorprothixene, thiothixene, haloperidol, butaperazine, prochlorperazine, carphenazine, bromperidol, loxapine, and molindone.

2. A method as claimed in claim 1, wherein said α

₂ -adrenergic receptor antagonist (i) is idazoxan.

3. A method as claimed in claim 1, wherein said α

₂ -adrenergic receptor antagonist (i) is administered in an amount from about 60 to 120 mg/day.

4. The method of claim 1, wherein said α

₂ -adrenergic receptor antagonist (i) is idazoxan, and wherein said antipsychotic neuroleptic drug (ii) is fluphenazine.

5. The method of claim 4, wherein the amount of said ingredients (i) and (ii) is therapeutically effective against schizophrenia and schizoaffective illnesses.